대한두경부종양학회지 (Korean Journal of Head & Neck Oncology)

  • 제35권2호
  • /
  • Pages.1-10
  • /
  • 2019
  • /
  • 1229-5183(pISSN)
  • /
  • 2586-2553(eISSN)
대한두경부종양학회 (The Korean Society for Head and Neck Oncology)
권호 표지
DOI QR코드

DOI QR Code

2019 미국 임상종양학회 두경부암 하이라이트

Highlights for the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting

  • 이윤규 (성균관대학교 의과대학 내과학교실, 강북삼성병원 혈액종양내과)
  • Lee, Yun-Gyoo (Division of Hematology & Medical Oncology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine)
  • 투고 : 2019.09.15
  • 심사 : 2019.10.31
  • 발행 : 2019.11.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

The 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, which took place May 31-June 4 in Chicago, drew more than 32,000 oncology specialists from around the world. The theme of 2019 ASCO conference was "Caring for Every Patient, Learning from Every Patient". Among the topics of interest covered were new approaches to surmount limited access to cancer care and the latest advances in targeted therapies for pancreatic, prostate cancers and soft tissue sarcomas. In the field of head and neck cancer, 8 oral abstracts and 75 poster abstracts were presented at this meeting. In this review, we are going to summarize the eight studies that have been presented orally. The topics are recurrent and/or metastatic head and neck squamous cell carcinoma for two abstracts (#6000, #6002), salivary duct carcinoma for one abstract (#6001), locally advanced nasopharyngeal carcinoma for two abstracts (#6003, #6004), oropharyngeal carcinoma for two abstracts (#6006, #6008), and oral cavity cancer for one abstract (#6007).

키워드

참고문헌

  1. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116-1127. https://doi.org/10.1056/NEJMoa0802656
  2. Rischin D, Harrington KJ, Greil R, Soulieres D, Tahara M, Castro Gd, et al. Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Journal of Clinical Oncology. 2019;37:6000-6000. https://doi.org/10.1200/jco.2019.37.15_suppl.6000
  3. Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017; 23:703-713. https://doi.org/10.1038/nm.4333
  4. Li BT, Shen R, Offin M, Buonocore DJ, Myers ML, Venkatesh A, et al. Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers (SGCs): Results from a phase II basket trial. Journal of Clinical Oncology. 2019;37:6001-6001. https://doi.org/10.1200/jco.2019.37.15_suppl.6001
  5. Guigay J, Fayette J, Dillies AF, Sire C, Kerger JN, Tennevet I, et al. Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: A multicenter, phase II GORTEC study. Ann Oncol. 2015;26:1941-1947. https://doi.org/10.1093/annonc/mdv268
  6. Guigay J, Fayette J, Mesia R, Lafond C, Saada-Bouzid E, Geoffrois L, et al. TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Journal of Clinical Oncology. 2019;37:6002-6002. https://doi.org/10.1200/jco.2019.37.15_suppl.6002
  7. Ma J, Zhang Y, Sun Y, Xie F, Hu W, Hu G, et al. Gemcitabine and cisplatin (GP) induction chemotherapy (IC) plus concurrent chemoradiotherapy (CCRT) versus CCRT alone in locoregionally advanced nasopharyngeal carcinoma (NPC): A phase 3, multicenter, randomized controlled trial. Journal of Clinical Oncology. 2019;37:6003-6003. https://doi.org/10.1200/jco.2019.37.15_suppl.6003
  8. Chen M-Y, Yang Q, Hong M, Hong M-H. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: Long-term results of a phase 3 multicenter randomized controlled trial. Journal of Clinical Oncology. 2019;37:6004-6004. https://doi.org/10.1200/jco.2019.37.15_suppl.6004
  9. Nichols AC, Theurer J, Prisman E, Read NE, Berthelet E, Tran E, et al. A phase II randomized trial for early-stage squamous cell carcinoma of the oropharynx: Radiotherapy versus trans-oral robotic surgery (ORATOR). Journal of Clinical Oncology. 2019;37:6006-6006. https://doi.org/10.1200/jco.2019.37.15_suppl.6006
  10. D'Cruz AK, Vaish R, Kapre N, Dandekar M, Gupta S, Hawaldar R, et al. Elective versus Therapeutic Neck Dissection in Node-Negative Oral Cancer. N Engl J Med. 2015;373:521-529. https://doi.org/10.1056/NEJMoa1506007
  11. Hasegawa Y, Tsukahara K, Yoshimoto S, Miura K, Yokoyama J, Hirano S, et al. Neck dissections based on sentinel lymph node navigation versus elective neck dissections in early oral cancers: A randomized, multicenter, non-inferiority trial. Journal of Clinical Oncology. 2019;37:6007-6007. https://doi.org/10.1200/jco.2019.37.15_suppl.6007
  12. Ferrarotto R, Bell D, Rubin ML, Lee JJ, Johnson JM, Goepfert R, et al. Checkpoint inhibitors assessment in oropharynx cancer (CIAO): Safety and interim results. Journal of Clinical Oncology. 2019;37:6008-6008. https://doi.org/10.1200/jco.2019.37.15_suppl.6008